Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

The Study of Abatacept in Combination With Etanercept

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00162279
Recruitment Status : Completed
First Posted : September 13, 2005
Last Update Posted : December 6, 2010
Information provided by:
Bristol-Myers Squibb

Brief Summary:
The Study was designed to look at the safety and efficacy of abatacept in combination with etanercept.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Drug: Abatacept Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 141 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Multi-Center, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Clinical Efficacy of Intravenous Infusions of BMS-188667 (10 mg/kg) Given Monthly in Combination With Subcutaneous Injections of Etanercept (25mg)Given Twice Weekly to Subjects With Active Rheumatoid Arthritis
Study Start Date : October 2000
Actual Primary Completion Date : February 2007
Actual Study Completion Date : February 2007

Resource links provided by the National Library of Medicine

Drug Information available for: Abatacept

Primary Outcome Measures :
  1. Abatacept combined with etanercept will have greater clinical efficacy compared to subjects receiving etanercept alone [ Time Frame: at 6 months ]

Secondary Outcome Measures :
  1. ACR 50 and 70 will be evaluated [ Time Frame: at 6 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All subjects who had completed the short term portion of IM101-101.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00162279

Layout table for location information
United States, Alabama
Local Institution
Huntsville, Alabama, United States
United States, California
Local Institution
La Jolla, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Angeles, California, United States
Local Institution
Palo Alto, California, United States
Local Institution
San Francisco, California, United States
United States, Colorado
Local Institution
Denver, Colorado, United States
United States, Florida
Local Institution
Ft. Lauderdale, Florida, United States
Local Institution
Titusville, Florida, United States
United States, Georgia
Local Institution
Rome, Georgia, United States
United States, Illinois
Local Institution
Chicago, Illinois, United States
United States, Maryland
Local Institution
Hagerstown, Maryland, United States
United States, Massachusetts
Local Institution
Boston, Massachusetts, United States
Local Institution
Springfield, Massachusetts, United States
United States, Minnesota
Local Institution
Duluth, Minnesota, United States
United States, Nebraska
Local Institution
Lincoln, Nebraska, United States
United States, New Jersey
Local Institution
New Brunswick, New Jersey, United States
United States, New Mexico
Local Institution
Los Alamos, New Mexico, United States
United States, New York
Local Institution
Albany, New York, United States
Local Institution
Mineola, New York, United States
Local Institution
New York, New York, United States
United States, North Dakota
Local Institution
Bismarck, North Dakota, United States
United States, Ohio
Local Institution
Cincinnati, Ohio, United States
United States, Oregon
Local Institution
Portland, Oregon, United States
United States, Pennsylvania
Local Institution
Duncansville, Pennsylvania, United States
Local Institution
Norristown, Pennsylvania, United States
United States, South Carolina
Local Institution
Charleston, South Carolina, United States
United States, Tennessee
Local Institution
Knoxville, Tennessee, United States
United States, Texas
Local Institution
Austin, Texas, United States
Local Institution
Dallas, Texas, United States
Local Institution
Temple, Texas, United States
United States, Utah
Local Institution
Salt Lake City, Utah, United States
United States, Washington
Local Institution
Edmonds, Washington, United States
Local Institution
Tacoma, Washington, United States
United States, Wisconsin
Local Institution
Glendale, Wisconsin, United States
Sponsors and Collaborators
Bristol-Myers Squibb
Layout table for additonal information Identifier: NCT00162279    
Other Study ID Numbers: IM101-101
First Posted: September 13, 2005    Key Record Dates
Last Update Posted: December 6, 2010
Last Verified: December 2010
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antirheumatic Agents